As such, the dose-dependent decrease in total ErbB2, Akt, Src, and GSK3 expression after ganetespib treatment in the ErbB2+ breast cancer cells (Fig. 4) is indicative of potential protein degradation. This evidence concerns the gene ERBB2 and breast cancer.